Investigation of the functional role of p-glycoprotein in limiting the oral bioavailability of lumefantrine

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 489-494

  Wahajuddin, ^a   Raju, Kanumuri S R ^a   Singh, Sheelendra P ^a   Taneja, Isha ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BENFLUMETOL; CYTOCHROME P450 3A; MULTIDRUG RESISTANCE PROTEIN; QUINIDINE; VERAPAMIL;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG PROTEIN BINDING; GASTROINTESTINAL ABSORPTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BIOLOGICAL AVAILABILITY; ETHANOLAMINES; FLUORENES; INTESTINAL ABSORPTION; MALE; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84891504196     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01382-13     Document Type: Article

References (33)

1. Wacher VJ, Salphati L, Benet LZ. 2001. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliv. Rev. 46: 89-102. http://dx.doi.org/10.1016/S0169-409X(00)00126-5.
2. de Waziers I, Cugnenc PH, Yang CS, Leroux JP, Beaune PH. 1990. Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J. Pharmacol. Exp. Ther. 253:387-394.
3. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. 1999. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39:361-398. http://dx.doi.org/10. 1146/annurev.pharmtox.39.1.361.
4. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, WrightonSA, Merion RM, Watkins PB. 1994. CYP3A gene expression in human gut epithelium. Pharmacogenetics 4:247-259. http://dx.doi.org/10.1097/00008571-199410000-00003.
5. Wacher VJ, Wu CY, Benet LZ. 1995. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 13:129-134. http://dx.doi.org/10.1002/mc.2940130302.
6. Benet LZ, Wu CY, Hebert MF, Wacher VJ. 1996. Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery. J. Controlled Release 39:139-143. http://dx.doi.org/10.1016/0168-3659(95)00147- 6.
7. Crowe A, Ilett KF, Karunajeewa HA, Batty KT, Davis TM. 2006. Role of P glycoprotein in absorption of novel antimalarial drugs. Antimicrob. Agents Chemother. 50:3504-3506. http://dx.doi.org/10.1128/AAC.00708-06.
8. Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ. 2000. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob. Agents Chemother. 44:697-704. http://dx.doi.org/10.1128/AAC.44.3.697-704.2000.
9. Wahajuddin, Singh SP, Raju KS, Nafis A, Puri SK, Jain GK. 2011. Intravenous pharmacokinetics, oral bioavailability, dose proportionality and in situ permeability of anti-malarial lumefantrine in rats. Malaria J. 10:293. http://dx.doi.org/10.1186/1475-2875-10-293.
10. Ashley EA, Stepniewska K, Lindegardh N, Annerberg A, Kham A, Brockman A, Singhasivanon P, White NJ, Nosten F. 2007. How much fat is necessary to optimize lumefantrine oral bioavailability? Trop. Med. Int. Health 12:195-200. http://dx.doi.org/10.1111/j.1365-3156.2006.01784.x.
11. White NJ, van Vugt M, Ezzet F. 1999. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin. Pharmacokinet. 37:105-125. http://dx.doi.org/10.2165/00003088-199937020-00002.
12. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, Shah VP, Lesko LJ, Chen ML, Lee VH, Hussain AS. 2002. Biopharmaceutics classification system: The scientific basis for biowaiver extensions. Pharm. Res. 19:921-925. http://dx.doi.org/10.1023/A:1016473601633
13. Fule R, Meer T, Sav A, Amin P. 2013. Solubility and dissolution rate enhancement of lumefantrine using hot melt extrusion technology with physicochemical characterisation. J. Pharm. Invest. 43:305-321. http://dx.doi.org/10.1007/s40005-013-0078-z.
14. Wong RP, Salman S, Ilett KF, Siba PM, Mueller I, Davis TM. 2011. Desbutyl-lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome. Antimicrob. Agents Chemother. 55:1194-1198. http://dx.doi.org/10.1128/ AAC.01312-10.
15. U. S. FDA. 19 April 2010. Drug transporters: interpretation and application of the International Transporter Consortium white paper and draft FDA guidance. White paper. U.S. FDA, Rockville, MD.
16. Dahan A, Amidon GL. 2009. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am. J. Physiol. Gastrointest. Liver Physiol. 297:G371-G377. http://dx.doi.org/10.1152/ajpgi.00102.2009.
17. Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Jarvinen T, Savolainen J. 2008. Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 7:255-270. http://dx.doi.org/10.1038/nrd2468.
18. Song NN, Li QS, Liu CX. 2006. Intestinal permeability of metformin using single-pass intestinal perfusion in rats. World J. Gastroenterol. 12: 4064-4070.
19. Varma MV, Panchagnula R. 2005. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situand in vivo. Eur. J. Pharm. Sci. 25:445-453. http://dx.doi.org/10.1016/j.ejps.2005.04. 003.
20. Wahajuddin, Singh SP, Patel K, Pradhan T, Siddiqui HH, Singh SK. 2011. Prediction of human absorption of a trioxane antimalarial drug (CDRI 99/411) using an in-house validated in situ single-pass intestinal perfusion model. Arzneimittelforschung 61:532-537. http://dx.doi.org/10.1055/s-0031-1296240.
21. Wahajuddin, Singh SP, Raju KS, Nafis A, Jain GK. 2012. Simultaneous determination of nine model compounds in permeability samples using RP-HPLC: application to prove the cassette administration principle in single pass intestinal perfusion study in rats. J. Pharm. Biomed. Anal. 67-68:71-76. http://dx.doi.org/10.1016/j.jpba.2012.03.048.
22. Neerati P, Ganji D, Bedada SK. 2011. Study on in situ and in vivo absorption kinetics of phenytoin by modulating P-glycoprotein with verapamil in rats. Eur. J. Pharm. Sci. 44:27-31. http://dx.doi.org/10.1016/j.ejps.2011.05. 005.
23. Wahajuddin, Singh SP, Jain GK. 2012. Gender differences in pharmacokinetics of lumefantrine and its metabolite desbutyl-lumefantrine in rats. Biopharm. Drug Dispos. 33:229-234. http://dx.doi.org/10.1002/bdd.1786.
24. Wahajuddin, Singh SP, Jain GK. 2009. Determination of lumefantrine in rat plasma by liquid-liquid extraction using LC-MS/MS with electrospray ionization: assay development, validation and application to a pharmacokinetic study. J. Chromatogr. B 877:1133-1139. http://dx.doi.org/10.1016/j.jchromb.2009.02.058.
25. Breedveld P, Beijnen JH, Schellens JH. 2006. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol. Sci. 27:17-24. http://dx.doi.org/10.1016/j. tips.2005.11.009.
26. Choi JS, Li X. 2005. The effect of verapamil on the pharmacokinetics of paclitaxel in rats. Eur. J. Pharm. Sci. 24:95-100. http://dx.doi.org/10.1016/j. ejps.2004.10.002.
27. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH. 2000. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst. 92:1651-1656. http://dx.doi.org/10.1093/jnci/92.20.1651.
28. Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, Schellens JH. 2002. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J. Clin. Oncol. 20:2943-2950. http://dx.doi.org/10.1200/JCO.2002.12.116.
29. Ezzet F, Mull R, Karbwang J. 1998. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether benflumetol) in malaria patients. Br. J. Clin. Pharmacol. 46:553-561.
30. Varma MV, Panchagnula R. 2005. Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability. J. Pharm. Sci. 94:1694-1704. http://dx.doi.org/10.1002/jps.20309.
31. Zakeri-Milani P, Valizadeh H, Tajerzadeh H, Azarmi Y, Islambolchilar Z, Barzegar S, Barzegar-Jalali M. 2007. Predicting human intestinal permeability using single-pass intestinal perfusion in rat. J. Pharm. Pharm. Sci. 10:368-379.
32. Varma MV, Sateesh K, Panchagnula R. 2005. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport. Mol. Pharm. 2:12-21. http://dx.doi.org/10.1021/mp0499196.
33. U.S. FDA. 2012. Drug administration guidance for industry: drug interaction studies - study design, data analysis, and implications for dosing and labeling. U.S. FDA, Rockville, MD.